Evidence map›Paper›PMID 41483630›Full record

ArticleESMO open2026

Corrigendum to "A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study)": [ESMO Open. Volume 10, Issue 9, (September 2025) 105571].

M Wakabayashi, H Taniguchi, A Makiyama, Y Sunakawa, H Takeda, K Arimizu, Y Okumura, C Inagaki, S Mitani, T Kudo and 6 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

M WakabayashiDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan; Department of Gastroenterology and Hepatology, Toho University Omori Medical Center, Tokyo, Japan.
H TaniguchiDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. Electronic address: hiroya.taniguchi@aichi-cc.jp.
A MakiyamaCancer Center, Gifu University Hospital, Gifu, Japan.
Y SunakawaDepartment of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
H TakedaDepartment of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
K ArimizuDepartment of Gastrointestinal and Medical Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan.
Y OkumuraDepartment of Gastrointestinal and Medical Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan.
C InagakiDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Osakasayama, Japan.
S MitaniDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Osakasayama, Japan.
T KudoDepartment of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
S YukiDepartment of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan.
N AkazawaDepartment of Gastroenterological Surgery, Sendai City Medical Center Sendai Open Hospital, Miyagi, Japan.
C KudoDepartment of Clinical Research, Aichi; Cancer Center Hospital, Nagoya, Japan.
K MoriClinical Research Center, Shizuoka Cancer Center, Nagaizumi, Japan.
T MatsudaDepartment of Gastroenterology and Hepatology, Toho University Omori Medical Center, Tokyo, Japan.
K MuroDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41483630
PMCPMC12805334

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.